Gastrointestinal Cancers

The combination of atezolizumab immunotherapy plus bevacizumab improves survival as well as significantly delaying deterioration in quality of life compared with the current standard of the targeted therapy sorafenib in the treatment of patients with unresectable hepatocellular carcinoma (HCC).

The FDA approval of avapritinib marks the first time a drug has been approved specifically for patients with GIST harboring PDGFRA exon 18 mutations, which are involved in approximately 10% of GIST cases.

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), also known as carcinoids and islet-cell tumors, are tumors of the neuroendocrine cells that occur in the gastrointestinal (GI) tract. GEP-NETs are heterogeneous and complex. Although relatively rare, GEP-NETs are more common than other tumors of the GI tract, including stomach and pancreatic carcinomas combined.